Adjuvant Chemotherapy for Biliary Tract Cancer After Curative Resection
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
This prospective, open-Label, comparative, randomized, controlled phase III trial was
designed to compare the clinical performance of gemcitabine with capecitabine vs.
capecitabine alone for patients with biliary tract cancer (BTC) after curative resection.
Phase:
Phase 3
Details
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital